Three humanized neutralizing antibodies to sclerostin, a glycoprotein secreted by osteocytes with a negative effect on the formation of bone tissue, are currently in clinical trials, under development, with preclinical and clinical evidence supporting their use in osteoporosis [64]. This evidence concerns the gene SOST and osteoporosis.